

### **Abridged Prescribing Information**

## **HYLAN POLYMER A & B G-F 20 Prefilled syringe 8 mg/ml SYNVISC®**

**COMPOSITION** Each pack contains one-prefilled syringe of Synvisc 2 ml

Content per ml (hylan G-F 20):

Each 1 ml contains: hylan polymer 8.0 mg, sodium chloride 8.5 mg, disodium hydrogen phosphate 0.16 mg, sodium dihydrogen phosphate hydrate 0.04 mg, water for injection q.s.

### **THERAPEUTIC INDICATIONS**

Hylan G-F 20 (Synvisc) is indicated:

For pain management in patients suffering with osteoarthritis of the knee, hip, shoulder and ankle.

For the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non pharmacologic therapy and to simple analgesics. For the treatment to decrease pain and discomfort allowing more extensive movement of the knee

### **DOSAGE AND ADMINISTRATION**

Synvisc is administered as a single intra-articular injection. Remove synovial fluid or effusion before injecting hylan G-F 20. Strict aseptic administration technique must be followed. Inject into the synovial space only, using if necessary, appropriate guidance such as fluoroscopy especially in joints such as the hip and shoulder. The recommended treatment regimen is one injection in the knee.

### **SAFETY-RELATED INFORMATION**

**Contraindications:** Synvisc should not be used in patients with known hypersensitivity (allergy) to hyaluronan (sodium hyaluronate) preparations. Synvisc should not be injected into the joint if there is venous or lymphatic stasis in the limb to be injected. Synvisc should not be used in infected or severely inflamed joints or in patients having skin disease or infections in the area of the injection site.

**Pregnancy and Lactation:** The safety and effectiveness of Synvisc has not been established in pregnant women. It is not known if Synvisc is excreted in human milk. The safety and effectiveness of Synvisc have not been established in lactating women.

**Warnings and Precautions:** Do not inject Synvisc intravascularly. Intravascular injections may cause systemic adverse events. Do not inject Synvisc extra-articularly or into the synovial tissues and capsule. Adverse events, generally in the area of the injection, have occurred following extra-articular injection of Synvisc-One. Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronan can precipitate in their presence. Remove any synovial fluid or effusion prior to injecting Synvisc.

As with any invasive joint procedure, it is recommended that the patient avoid any strenuous activities for approximately 48 hours following the intra-articular injection, and resume full activities within a few days. Synvisc have not been tested in pregnant women or children  $\leq$  21 year of age. Synvisc contains small amounts of avian protein and should not be used in patients with related hypersensitivities. Do not inject anesthetics or other medications into the knee joint during Synvisc therapy.

**Adverse Reactions:** Adverse events involving the injected joint that may occur after intra-articular injections of Synvisc are Transient pain, Transient swelling and/or Effusion. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported. Cases of acute inflammation, characterized by joint pain, swelling, effusion and sometimes joint warmth and/or stiffness, have been reported following an intra-articular injection of Synvisc.

*For full prescribing information please contact Sanofi-Synthelabo (India) Private Limited, Sanofi House, CT Survey No 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072*

Source: CCDS version 3 dated 14<sup>th</sup> April 2014

Updated: June 2015